This article is more than 5 years old. Information may no longer be current.
Advances in Ulcerative Colitis Management: Targeting Inflammation to Achieve Remission Across the Disease Spectrum
Click Here to Manage Email Alerts
Although ulcerative colitis (UC) is globally one of the most common inflammatory bowel diseases, many patients continue to receive suboptimal therapy. Outcomes in UC are diminished by multiple factors, including physician uncertainty regarding approaches to treatment for newly diagnosed patients, confusion regarding the role of biologic and conventional therapies, and a lack of guidance on patient selection for early intensive treatment. As the therapeutic landscape for UC continues to evolve, physicians need to be aware of how these agents can be used to personalize therapy and optimize patient outcomes. In this activity, leading gastroenterologists will discuss the most current therapeutic advancements in the management of patients with UC.
Learning Objectives:
Upon completing this activity, participants should be able to:
- Differentiate available and emerging therapies for the management of ulcerative colitis based on mechanism of action, efficacy, safety, and recommended usage.
- Apply knowledge of mechanisms of action, efficacy, safety, and recommended usage of available agents for ulcerative colitis management to clinical decision-making.
- Utilize appropriate prognostic indicators and disease activity assessment to individualize therapy for patients with ulcerative colitis.
- Review the clinical significance of early disease detection and treatment as well as effective therapeutic strategies for difficult-to-treat patients with ulcerative colitis, including those who are refractory to conventional treatment or have limited access to care.
To see this Education Lab activity, click here.
Overview
Author(s)/Faculty: David T. Rubin, MD; Stephen B. Hanauer, MD; Uma Mahadevan, MD; William J. Sandborn, MD
Source: Healio Gastroenterology Education Lab
Type: Multimedia
Articles/Items: 8
Release Date: 12/7/2015
Expiration Date: 12/8/2016
Credit Type: CME
Number of Credits: 1.5
Cost: Free
Provider: Vindico Medical Education
CME Information
Provider Statement: This continuing medical education activity is provided by Vindico Medical Education.
Support Statement: This activity is supported by an educational grant from Salix, A Division of Valeant Pharmaceuticals North America, LLC.
Target Audience: The intended audience for this activity is gastroenterologists and other health care professionals involved in the treatment of patients with ulcerative colitis.